Niagen Bioscience (NASDAQ:NAGE) Stock Gets Price Target Trim from Canaccord Genuity Group

Niagen Bioscience (NASDAQ:NAGE) had its target price trimmed by Canaccord Genuity Group from $10.00 to $9.00 in a report published on Friday morning,Benzinga reports. The firm currently has a buy rating on the stock.

A number of other equities analysts have also weighed in on the company. Roth Capital reiterated a “buy” rating on shares of Niagen Bioscience in a research note on Wednesday, August 5th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Niagen Bioscience in a research note on Thursday, October 15th. Finally, Freedom Capital raised Niagen Bioscience to a “strong-buy” rating in a research note on Monday, July 6th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $10.00.

Niagen Bioscience Price Performance

Shares of NASDAQ:NAGE opened at $2.33 on Friday. Niagen Bioscience has a 52 week low of $2.32 and a 52 week high of $7.95. The company has a market capitalization of $185.57 million, a price-to-earnings ratio of 12.95 and a beta of 2.02. The firm has a 50 day moving average of $2.86 and a 200 day moving average of $3.93.

Niagen Bioscience (NASDAQ:NAGE) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $0.01 EPS for the quarter, hitting the consensus estimate of $0.01. Niagen Bioscience had a net margin of 12.39% and a return on equity of 17.95%. The firm had revenue of $29.78 million during the quarter, compared to analyst estimates of $29.95 million. On average, sell-side analysts expect that Niagen Bioscience will post 0.10 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. State of Wyoming lifted its holdings in shares of Niagen Bioscience by 327.0% in the 3rd quarter. State of Wyoming now owns 63,108 shares of the company’s stock valued at $184,000 after purchasing an additional 48,329 shares during the last quarter. Abel Hall LLC purchased a new stake in shares of Niagen Bioscience in the third quarter valued at approximately $99,000. SteelPeak Wealth LLC increased its holdings in shares of Niagen Bioscience by 2.2% in the 3rd quarter. SteelPeak Wealth LLC now owns 3,577,435 shares of the company’s stock valued at $10,446,000 after purchasing an additional 77,306 shares in the last quarter. Tidal Investments LLC purchased a new stake in shares of Niagen Bioscience during the 2nd quarter worth approximately $394,000. Finally, Squarepoint Ops LLC increased its position in shares of Niagen Bioscience by 33.3% in the second quarter. Squarepoint Ops LLC now owns 123,054 shares of the company’s stock valued at $393,000 after buying an additional 30,711 shares in the last quarter. Institutional investors and hedge funds own 15.41% of the company’s stock.

Niagen Bioscience Company Profile

Niagen Bioscience, Inc develops and commercializes science-based products designed to support healthy aging and cellular health. The company focuses on NAD+ biology, including nicotinamide riboside (NR), a form of vitamin B3 that serves as a precursor to NAD+, a coenzyme involved in cellular energy production and other biological processes.

Its principal consumer product is Tru Niagen, an NR-based dietary supplement sold through the company’s direct-to-consumer website and retail and distribution channels.